Innealta Capital’s Immunovant IMVT Stock Holding History

Innealta Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-59	Closed	-$1.56K	–	886
2024 Q2	$1.56K	Buy	+59	New	+$1.68K	﹤0.01%	1171

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Innealta Capital's IMVT Position: Q3 2024 in Review

Innealta Capital sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 59 shares — an estimated $1.56K sold.

Innealta Capital first reported a position in IMVT in Q2 2024 and held it in 1 quarter. The position peaked at $1.56K in Q2 2024. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

Innealta Capital reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 59 Immunovant shares in Q3 2024, an estimated $1.56K.
Innealta Capital first reported a position in Immunovant in Q2 2024 and held it in 1 quarter.
Innealta Capital's Immunovant position peaked at $1.56K in Q2 2024.
181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.